Many drug companies have conceded that the days of super-sized price increases, which sometimes occurred multiple times per year, are gone for now. President Trump's rhetoric around price controls and public outrage over high drug costs have forced the industry to soften, as it heavily lobbies politicians behind the scenes.

So does that mean the drug industry will lose a lot of money? Not really. First-quarter reports show many of the largest pharmaceutical companies increased their profits compared with the same period last year. Sales of some drugs lagged, but companies still hiked list prices by high single digits — well above general inflation.

Expand chart
Data: Company earnings reports; Chart: Andrew Witherspoon / Axios

A handful of major pharmaceutical firms reported higher first-quarter earnings this week. Part of that was due to cutting back on operating expenses, like research and marketing, but list prices were also raised for many drugs.

  • Amgen: Profit jumped 9%, surpassing $2 billion, even though sales declined. Amgen raised the list price of its major rheumatoid arthritis drug Enbrel by 8.4% in January, according to data obtained by Axios, as a way to offset competing drugs.
  • AbbVie: Profit soared 26%. Arthritis blockbuster drug Humira, which got an 8.4% list price boost in January, continues to be the company's biggest earner.
  • Bristol-Myers Squibb: A 32% jolt to earnings came thanks to big sales of cancer drug Opdivo.
  • Celgene: First-quarter profit almost hit $1 billion as demand for multiple myeloma drug Revlimid took off. Celgene raised the list price of Revlimid by 8% in January.
  • Biogen: Sales of its multiple sclerosis drug Tecfidera basically stayed the same despite an 8% price hike in January. Biogen's profit declined, but it was still around three-quarters of a billion dollars.
  • Eli Lilly: Lost money due to severance and acquisition costs, not because people weren't buying their drugs.

Go deeper

Americans reflect on Independence Day amid racism reckoning

A Black Lives Matter banner and a United States flag on the facade of the U.S. embassy building in Seoul, South Korea. Photo: Simon Shin/SOPA Images/LightRocket via Getty Images

America's leaders are rethinking how they view Independence Day, as the country reckons with the historic, unequal treatment of people of color during a pandemic which has disproportionately affected nonwhite Americans.

Why it matters: The country’s legacy of racism has come into sharp focus in the weeks of protests following the death of George Floyd while in Minneapolis police custody. From Confederate statues to Mount Rushmore, Americans are reexamining the symbols and traditions they elevate and the history behind them.

Updated 12 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 7 p.m. ET: 11,031,905 — Total deaths: 523,777 — Total recoveries — 5,834,337Map.
  2. U.S.: Total confirmed cases as of 7 p.m. ET: 2,788,395 — Total deaths: 129,306 — Total recoveries: 790,404 — Total tested: 34,213,497Map.
  3. States: ICU beds in Arizona's hot spot reach near capacity.
  4. Public health: The states where face coverings are mandatory Fauci says it has been a "very disturbing week" for the spread of the coronavirus in the U.S.
  5. Economy: The economy may recover just quickly enough to kill political interest in more stimulus.
15 hours ago - Sports

Washington Redskins to review team name amid public pressure

Photo: Patrick McDermott/Getty Images

The Washington Redskins have announced they will be conducting a review of the team's name after mounting pressure from the public and corporate sponsors.

Why it matters: This review is the first formal step the Redskins are taking since the debate surrounding the name first began. It comes after weeks of discussions between the team and the NFL, the team said.